Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||HY-16462 + JQ1|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|HY-16462||HY16462|HY 16462||CDK9 Inhibitor 16||HY-16462 is a CDK9 inhibitor, which has potential antitumor activity (PMID: 31000582).|
|JQ1||BET Inhibitor (Pan) 27||JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression, increased cell death, reduced macrophage immunosuppression, and inhibition of tumor growth (PMID: 24231268, PMID: 31018997, PMID: 30906568).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||HY-16462 + JQ1||Preclinical - Cell culture||Actionable||In a preclinical study, HY-16462 and JQ1 treatment synergistically inhibited growth of a triple-negative breast cancer cell line in culture (PMID: 31000582).||31000582|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|